DK1002108T3 - Anvendelse af MHC klasse II-ligander som adjuvans til vaccination af LAG-3 ved cancerbehandling - Google Patents

Anvendelse af MHC klasse II-ligander som adjuvans til vaccination af LAG-3 ved cancerbehandling

Info

Publication number
DK1002108T3
DK1002108T3 DK98945090T DK98945090T DK1002108T3 DK 1002108 T3 DK1002108 T3 DK 1002108T3 DK 98945090 T DK98945090 T DK 98945090T DK 98945090 T DK98945090 T DK 98945090T DK 1002108 T3 DK1002108 T3 DK 1002108T3
Authority
DK
Denmark
Prior art keywords
mhc class
lag
adjuvant
vaccination
ligands
Prior art date
Application number
DK98945090T
Other languages
English (en)
Inventor
Frederique Triebel
Original Assignee
Roussy Inst Gustave
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Applied Research Systems filed Critical Roussy Inst Gustave
Application granted granted Critical
Publication of DK1002108T3 publication Critical patent/DK1002108T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK98945090T 1997-07-25 1998-07-23 Anvendelse af MHC klasse II-ligander som adjuvans til vaccination af LAG-3 ved cancerbehandling DK1002108T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97401800A EP0893507A1 (en) 1997-07-25 1997-07-25 Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment

Publications (1)

Publication Number Publication Date
DK1002108T3 true DK1002108T3 (da) 2006-08-21

Family

ID=8229825

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98945090T DK1002108T3 (da) 1997-07-25 1998-07-23 Anvendelse af MHC klasse II-ligander som adjuvans til vaccination af LAG-3 ved cancerbehandling

Country Status (19)

Country Link
US (2) US6410509B1 (da)
EP (3) EP0893507A1 (da)
JP (1) JP4723722B2 (da)
KR (1) KR100603075B1 (da)
CN (1) CN1184320C (da)
AT (2) ATE478956T1 (da)
AU (1) AU753738B2 (da)
BR (1) BR9811037A (da)
CA (2) CA2293805C (da)
DE (2) DE69841866D1 (da)
DK (1) DK1002108T3 (da)
EA (3) EA003740B1 (da)
EE (1) EE200000039A (da)
ES (1) ES2262242T3 (da)
IL (2) IL134212A0 (da)
NO (1) NO20000378L (da)
PT (1) PT1002108E (da)
UA (1) UA75322C2 (da)
WO (1) WO1999004810A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1295895B1 (en) * 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
PL1897548T5 (pl) * 2003-02-28 2025-03-17 The Johns Hopkins University Regulacja komórek T
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
FR2868781B1 (fr) * 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2044949A1 (en) * 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
MX345739B (es) 2010-11-10 2017-02-14 Laboratorios Leti S L * Nuevo adyuvante.
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
US9683048B2 (en) 2014-01-24 2017-06-20 Novartis Ag Antibody molecules to PD-1 and uses thereof
CN103751778B (zh) * 2014-01-28 2016-09-28 复旦大学 3′-脱氧腺苷在制备广谱疫苗增效的免疫佐剂中的应用
JP6576962B2 (ja) 2014-03-14 2019-09-18 ノバルティス アーゲー Ｌａｇ−３に対する抗体分子およびその使用
JP6423889B2 (ja) 2014-10-07 2018-11-14 サイトリミック株式会社 Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
WO2016094639A1 (en) * 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Mini-intronic plasmid dna vaccines in combination with lag3 blockade
GB201500374D0 (en) * 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
WO2016143816A1 (ja) 2015-03-09 2016-09-15 日本電気株式会社 Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
JP6311094B2 (ja) 2015-04-07 2018-04-18 サイトリミック株式会社 医薬
JP6925980B2 (ja) 2015-05-13 2021-08-25 アジェナス インコーポレイテッド がんの処置および予防のためのワクチン
EP3322431A2 (en) 2015-07-16 2018-05-23 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US10265379B2 (en) 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
WO2017046409A1 (en) 2015-09-18 2017-03-23 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
ES2972560T3 (es) 2016-10-11 2024-06-13 Nec Corp Medicamento que comprende un agonista de receptores tipo Toll, proteína LAG-3, un péptido derivado de HSP70 y un péptido derivado de GPC3
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN113271970A (zh) * 2018-09-27 2021-08-17 健诺西生物科学公司 治疗方法
JP2020138940A (ja) 2019-02-28 2020-09-03 テルモ株式会社 治療方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226414A (en) * 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
WO1990001870A1 (en) * 1988-08-22 1990-03-08 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Retroviral vectors expressing soluble cd4; a gene therapy for aids
JPH02231083A (ja) * 1988-08-31 1990-09-13 Eisai Co Ltd 組換ナチュラルキラー細胞活性化因子
IL93599A0 (en) * 1989-03-03 1990-12-23 Microgenesys Inc Kit and/or composition for the prevention or treatment of aids
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
PT681483E (pt) * 1993-01-26 2005-11-30 Wyeth Corp Composicoes e metodos para distribuicao de material genetico
SE510135C2 (sv) * 1994-05-05 1999-04-19 Berol Nobel Ab Vattenhaltig suspension av en cellulosaeter, sätt för dess framställning samt komposition
PT758383E (pt) * 1994-05-06 2007-05-31 Roussy Inst Gustave Fracções polipeptídicas solúveis da ptroteína lag-3; processo de produção; composição terapêutica; anticorpos anti-idiotipo
JPH10503654A (ja) * 1994-08-05 1998-04-07 ワーナー−ランバート・コンパニー レトロウイルスの感染の治療におけるトランスドミナント・ネガティブ・レトロウイルス・インテグラーゼの使用方法
EP0787151A1 (en) * 1994-12-07 1997-08-06 F. Hoffmann-La Roche Ag Monoclonal antibody fragments having immunosuppressant activity
CZ186897A3 (cs) * 1994-12-23 1998-03-18 Laboratoires Om S. A. Použití molekul, schopných vázat MHC-II nebo napodobujících MHC-II pro výrobu farmaceutického prostředku
EP0869803B1 (en) * 1995-12-28 2003-04-16 The Johns Hopkins University School Of Medicine Allogeneic paracrine cytokine tumor vaccines

Also Published As

Publication number Publication date
EA200000161A1 (ru) 2000-10-30
EP0893507A1 (en) 1999-01-27
EA200200565A1 (ru) 2002-10-31
NO20000378D0 (no) 2000-01-25
UA75322C2 (en) 2006-04-17
CA2293805C (en) 2011-05-03
WO1999004810A2 (en) 1999-02-04
EP1002108A2 (en) 2000-05-24
EP1698701A1 (en) 2006-09-06
ES2262242T3 (es) 2006-11-16
EA003740B1 (ru) 2003-08-28
KR100603075B1 (ko) 2006-07-20
EA005405B1 (ru) 2005-02-24
CA2732570A1 (en) 1999-02-04
EP1002108B1 (en) 2006-04-26
JP4723722B2 (ja) 2011-07-13
IL134212A0 (en) 2001-04-30
US20020192195A1 (en) 2002-12-19
EE200000039A (et) 2000-10-16
CA2293805A1 (en) 1999-02-04
ATE478956T1 (de) 2010-09-15
KR20010021706A (ko) 2001-03-15
NO20000378L (no) 2000-01-25
EA200300092A1 (ru) 2003-06-26
JP2001510806A (ja) 2001-08-07
PT1002108E (pt) 2006-09-29
BR9811037A (pt) 2000-08-01
DE69834330T2 (de) 2007-03-29
US6410509B1 (en) 2002-06-25
ATE324455T1 (de) 2006-05-15
CN1265149A (zh) 2000-08-30
CN1184320C (zh) 2005-01-12
CA2732570C (en) 2014-11-18
US7109026B2 (en) 2006-09-19
IL134212A (en) 2012-03-29
HK1030014A1 (en) 2001-04-20
WO1999004810A3 (en) 1999-07-08
DE69834330D1 (de) 2006-06-01
AU9254798A (en) 1999-02-16
AU753738B2 (en) 2002-10-24
EP1698701B1 (en) 2010-08-25
DE69841866D1 (de) 2010-10-07

Similar Documents

Publication Publication Date Title
DK1002108T3 (da) Anvendelse af MHC klasse II-ligander som adjuvans til vaccination af LAG-3 ved cancerbehandling
BR0116169A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto.
BR8300475A (pt) Composto, composicao farmaceutica, processo para tratamento de infeccao virotica em um animal de sangue quente ou de sangue frio, e processo para a preparacao de tal composto
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
DK1382348T3 (da) Polynukleotidvaccineformulering, især til behandling af bovin luftvejssygdom
ID21529A (id) Metode dan komposisi untuk pengobatan dan pencegahan tumor, gangguan yang berhubungan dengan tumor dan kakeksia
EP1005368A4 (en) USE OF NON-METHYLATED CpG DINUCLEOTIDE AS ADJUVANS
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
DK16487A (da) Vacciner til oral indgift
DK0955995T3 (da) Anvendelse af komplekser til fremstilling af præparater til behandling af sensibel hud, fremgangsmåde til fremstilling af hypoallergene præparater
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
DE69130071D1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
CA2034484A1 (en) Radioimmunotherapy using .alpha.-particles emission
DE60015084D1 (de) Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
PT845998E (pt) Medicamentos para imunoterapia contendo anticorpos que reconhecem de forma especifica o antigenio mhcii de um paciente a ser tratado
PT854924E (pt) Antigenios de leishmania para uso na terapia e diagnostico da leishmaniose
DK0983072T4 (da) Fruktanholdige sammensætninger til forebyggelse og behandling af coloncancer
ATE118351T1 (de) Wirkung von hormonen.
EP1037918A4 (en) METHOD AND COMPOSITIONS FOR INCREASING THE EFFICIENCY OF VACCINALS USING CHEMOKINES
DK188680A (da) Fremgangsmaade til fremstilling af 6-substituerede 11-alkylenmorphantridiner
WO2000055194A3 (en) Tuberculosis antigens and methods of use therefor
WO1998035045A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
WO2002072013A8 (en) Method of treating malignancies through induction of blood immune responses
BR0212446A (pt) Uso de 4-piridilmetilftalazinas para tratamento de câncer
DK0835309T3 (da) Vaccine imod infektiøse agenser, præparat til behandling og forebyggelse af HIV infektioner